OPK Opko Health, Inc.

6.33
-0.02  -0%
Previous Close 6.35
Open 6.41
Price To book 1.68
Market Cap 3.54B
Shares 559,388,000
Volume 2,868,020
Short Ratio 13.87
Av. Daily Volume 4,585,150

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b trial to be initiated 2H 2017.
TT701 (selective androgen receptor modulator)
Benign Prostatic Hyperplasia (BPH)
Phase 2b trial to be initiated in early 2018.
OPK88004
Obesity and diabetes
Phase 2 trial to be initiated 2H 2017.
RAYALDEE
Secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) - Stage 5
Phase 3 data released December 30, 2016 - primary endpoint not met.
hGH-CTP
Adults - growth hormone deficiency
Phase 3 initiation announced December 30, 2016.
hGH-CTP
Children - growth hormone deficiency
Announced June 21 2016 FDA Approval
RAYALDEE
Secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) and vitamin D insufficiency - Stage 3 and 4
Phase 2 ongoing as of May 2017.
Factor VIIa-CTP
Hemophilia
Phase 3 to be initiated 2H 2017.
Fermagate Tablets
hyperphosphatemia in CKD patients on chronic hemodialysis
Approved September 2, 2015.
Rolapitant
Prevention of chemotherapy induced nausea and vomiting, or CINV

Latest News

  1. Is the Options Market Predicting a Spike in Opko Health (OPK) Stock?
  2. 3 Value Stocks You Might Not Have Thought Of
  3. Xenetic Biosciences Receives Program Update from Partner Shire’s Phase 1/2 Study Evaluating SHP656 in Development as a Long-acting Treatment for Hemophilia A
  4. MabVax Therapeutics Announces the Closing of its $4.1 Million Public Offering
  5. OPKO Health’s 4Kscore® Test Highlighted in Podium Presentation at 112th American Urological Association Annual Meeting
  6. Xenetic Biosciences Reports 2017 First Quarter Financial Results and Provides Business Update
  7. Edited Transcript of OPK earnings conference call or presentation 9-May-17 8:30pm GMT
  8. OPKO Announces Multiple Presentations at the 112th American Urological Association Annual Meeting 
  9. OPKO Health reports 1Q loss
  10. CORRECTION -- OPKO Health Inc.
  11. OPKO Health Reports 2016 Financial and Operating Results
  12. Investor Network: OPKO Health, Inc. to Host Earnings Call
  13. Xenetic Biosciences to Host 2017 First Quarter Update Conference Call
  14. ETFs with exposure to OPKO Health, Inc. : May 8, 2017
  15. OPKO Health to Announce 2017 First Quarter Financial Results on May 9, 2017
  16. Xenetic Biosciences Presents Case Study of PolyXen™ Platform Technology at the 13th Annual Protein Engineering Summit (PEGS) Boston
  17. ETFs with exposure to OPKO Health, Inc. : April 27, 2017
  18. Cocrystal Pharma Receives Investment Through Private Placement
  19. Xenetic Biosciences’ PolyXen™ Platform Technology Accepted for Poster Presentation at the 13th Annual Protein Engineering Summit (PEGS) Boston
  20. 3 Beaten-Up Healthcare Stocks: Are They Bargains?